Logo image
Back
Mismatch negativity in bipolar disorder: A neurophysiological biomarker of intermediate effect?
Journal article   Peer reviewed

Mismatch negativity in bipolar disorder: A neurophysiological biomarker of intermediate effect?

Daniel F Hermens, K M Chitty and M Kaur
Schizophrenia Research, Vol.191, pp.132-139
2018
DOI: https://doi.org/10.1016/j.schres.2017.04.026
Appears in  Thompson Institute Research Collection
url
https://doi.org/10.1016/j.schres.2017.04.026View
Published Version

Abstract

mismatch negativity bipolar disorder glutamate NMDA receptor neurophysiological biomarker schizophrenia Other Collaborations Thompson Institute Special Collection
The event-related potential, mismatch negativity (MMN), has been touted as a robust and specific neurophysiological biomarker of schizophrenia. Earlier studies often included bipolar disorder (BD) as a clinical comparator and reported that MMN was significantly impaired only in schizophrenia. However, with the increasing number of MMN studies of BD (with larger sample sizes), the literature is now providing somewhat consistent evidence of this biomarker also being perturbed in BD, albeit to a lesser degree than that observed in schizophrenia. Indeed, two meta-analyses have now shown that the effect sizes in BD samples suggest a moderate impairment in MMN, compared to the large effect sizes shown in schizophrenia. Pharmacologically, MMN is an extremely useful non-invasive probe of glutamatergic (more specifically, N-methyl-d-aspartate [NMDA] receptor) disturbances and this system has been implicated in the pathophysiology of both schizophrenia and BD. Therefore, it may be best to conceptualize/utilize MMN as an index of a psychopathology that is shared across psychotic and related disorders, rather than being a diagnosis-specific biomarker. More research is needed, particularly longitudinal designs including studies that assess MMN over an individual's life course and then examine NMDA receptor expression/binding post-mortem. At this point and despite a disproportionate amount of research, the current evidence suggests that with respect to BD, MMN is a neurophysiological biomarker of intermediate effect. With replication and validation of this effect, MMN may prove to be an important indicator of a common psychopathology shared by a significant proportion of individuals with schizophrenia and bipolar spectrum illnesses. © 2017 Elsevier B.V.

Details

Metrics

1 File views/ downloads
474 Record Views
34 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Psychiatry

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image